Iris recognition system using quality metrics

Information

  • Patent Grant
  • 8280119
  • Patent Number
    8,280,119
  • Date Filed
    Friday, December 5, 2008
    15 years ago
  • Date Issued
    Tuesday, October 2, 2012
    11 years ago
Abstract
A system for iris recognition using a set of quality metrics, which may include eye image validation, blur assessment, offset, gazing, obscuration, visibility, and the like. These metrics may be established as quantitative measures which can automatically assess the quality of eye images before they are processed for recognition purposes. Quadrant iris analysis, histograms, map processing enhancements, and multi-band analysis may be used in aiding in the iris recognition approach.
Description
BACKGROUND

The present invention pertains to biometrics and particularly to identification of persons using biometrics. More particularly, the invention refers to identification via eye images.


SUMMARY

The invention is an iris recognition system using iris quality metrics on acquired eye images.





BRIEF DESCRIPTION OF THE DRAWING


FIG. 1 is a diagram of the architecture of the present image analysis system;



FIG. 2 is a diagram for eye image validation;



FIGS. 3
a, 3b, 3c and 4 are diagrams for image blur assessment;



FIG. 5 shows a diagram and information for eye gazing and offset determinations;



FIGS. 6
a and 6b show information and a diagram relative to eye obscuration;



FIGS. 7
a and 7b show information and a diagram pertaining to quadrant based iris segmentation analysis;



FIGS. 8 and 9 are histograms showing pixel clustering based on distribution; and



FIG. 10 is a diagram of one, two and three banks of code bits related to iris analysis.





DESCRIPTION

The present invention may include methods and apparatus for developing quantitative measures that can automatically assess the quality of iris images before being processed for iris recognition.


Digital eye images are often subject to a wide variety of distortions during acquisitions, transmission and reproduction any of which may result in degradation of iris recognition performance.


Several patent applications may be relevant to the present invention. U.S. patent application Ser. No. 10/979,129, filed Nov. 3, 2004, is hereby incorporated by reference. U.S. patent application Ser. No. 11/275,703 filed Jan. 25, 2006, is hereby incorporated by reference. U.S. patent application Ser. No. 11/372,854, filed Mar. 10, 2006, is hereby incorporated by reference. U.S. patent application Ser. No. 11/681,614, filed Mar. 2, 2007, is hereby incorporated by reference. U.S. patent application Ser. No. 11/043,366, filed Jan. 26, 2005, is hereby incorporated by reference. U.S. patent application Ser. No. 10/655,124, filed Sep. 5, 2003, is hereby incorporated by reference. U.S. patent application Ser. No. 11/672,108, filed Feb. 7, 2007, is hereby incorporated by reference. U.S. patent application Ser. No. 11/681,751, filed Mar. 2, 2007, is hereby incorporated by reference. U.S. patent application Ser. No. 11/681,662, filed Mar. 2, 2007, is hereby incorporated by reference. U.S. patent application Ser. No. 11/675,424, filed Feb. 15, 2007, is hereby incorporated by reference. U.S. patent application Ser. No. 11/382,373, filed May 9, 2006, is hereby incorporated by reference.


The present invention may include an implementation of a set of appropriate quantitative iris image quality metrics (IQM's). The IQM's may be defined on the basis of image features based on the acquisition performance. The quality of the image should correlate well with subjective iris processes. The IQM's may be integrated into a processing procedure to assess the quality of the iris image before and through out the iris recognition process. Based upon the evaluation of these metrics, a case based reasoning (CBR) approach may be executed to process the iris image based upon its quality.


It appears desirable to assess the quality of an eye image in real-time as a quality control procedure. This may allow poor image acquisition to be corrected through recapture and facilitate acquisition of the best possible image within the capture time window configured in the system. This may result in a process of more good quality iris images that can improve the iris identification accuracy and the integrity of iris recognition systems. A perfectly captured iris pattern under ideal conditions would illustrate clearly the texture of an iris that can be captured in a unique iris barcode. However, many factors such eye closure, obscuration, off-angle eyes, occlusions, and imperfect acquisition embedded in electronic noise, non-uniform illumination, different sensor wavelength sensitivity, pupil dilation, and specular light reflections, may cause the captured iris map to be far from having ideal quality. Smearing, blurring, defocus and poor resolution may result in the capture of very poor quality images as that will have a negative impact on even iris segmentation and/or feature extraction.


The present metrics may be used to improve upon the iris recognition using quadrant based analysis (starting from sclera edges to lid edges) and to extract iris features in constructing the iris polar map based upon the computed IQM's of the digital iris image. Based upon the amount of the artifacts, from obscuration, occlusion, or blurring or other effects, a process may be applied based upon the case based (CBR) reasoning approach.


IQM1 through IQM6 may be defined herein. IQM1 is eye validation. Eye validation may be assessed using the pupil edges (i.e., inner border of the iris) and determining how they fit to an elliptic model. One may analyze the model fitting into multi-stages where the edges are analyzed against an elliptic fit, and then to a circular fit. If either model fails, presumably because of an obscured eye, one may mask the upper lids and re-assess only the sclera and bottom lids against a model fit. The displacement of the curve from the model may be a measure of the quality of the eye.


IQM2 is blur amount. Properties of a neighborhood pixel distribution may be considered using a gradient of the iris texture. By assumption, the isotropic derivative of an image may show located edges at the borders of the iris consistently regardless of image quality (blur or focused images), which means a quantified amount of edges are expected to be in the image gradient as a function of the expected range of at least the inner border of the iris. The method of locating other edges is characteristic of the “gradient filter” family of edge detection filters. So for non-blur images, one may expect additional detected edges which exceed the amount associated with the inner borders. Thus, an image may be declared non-blur if the value of the cumulative sum of the gradient exceeds the expected range of the inner border of the iris.


There may be several scores for quality and matching. One is quality (Q1) relating to the query which should be 100 percent. Another is quality (Q2) of the probe or image. Still another score (M) is a matching score. The two scores, Q2 and M, are the scores which may be used in the present approach. IQMs 1, 2, 5 and 6 may be relevant to decision making in matching subjects and be used to tailor difference processes for different acquisition scenarios.


IQM3 may be an off angle or gazing measure of an eye in an image. The off angle may be assessed in an iris outer boundary shape fitting. One may measure the ratio between the major and minor axis of the elliptic fit of the pupil which can be a good indicator of the off angle or gazing of the eye.


IQM4 is a simple test of the location of the eye within the eye image. If the eye is close to the edges of the image by at least the expected maximum size of an iris radius, it can be considered an offset eye as it may not contain the entire bounds of the iris.


IQM5 is an amount of iris exposure within the iris map. IQM6 is similar to IQM1 but is applied to the outer border of the iris rather than the inner border.


The logical flow of processes may be influenced by the quality of the iris. An architecture design of the solution using the IQM's is described herein. Several procedures of the invention may be implemented with an algorithm. The segmentation analysis may be reconfigured based upon a quadrant approach where one uses a POSE (polar segmentation) technique (U.S. patent application Ser. No. 11/043,366, filed Jan. 26, 2005). The POSE type segmentation may start at the sclera edges and expand the edge detection to the lids quadrants (obscured areas). In the presence of obscuration (detected using the discontinuity in the derivative of the edge curve at the lid quadrants), one may mask the iris map accordingly based upon the amount of obscurations. Two selective operations may be defined. One is to mask the lid region entirely for heavy obscuration. Another is, for partial obscuration, to use the two breaking points of the discontinuity on the curve to interpolate a linear curve and extract just the iris pixels contained between the constructed line and pupil borders while masking the region outward the curve.


One may also model the iris map intensity using normal distributions to identify any outliers that do not fit the iris profile. The procedure may detect any artifacts due to reflection and or to some missed edges in the segmentation process.


To extend to at-a-distance applications, some of the algorithm procedures may require exhaustive processes which include Hough transforms. Some issues with a Hough method may include requiring threshold values to be chosen for edge detection, which may result into critical information (e.g., edge points) being removed/missed, and thus resulting in a failure to detect the iris or pupil regions.



FIG. 1 is a diagram of the architecture of the present invention or system 10. The first item is a locate-eye function block 11 which contains an eye finder 12. Upon finding an eye, the finder 12 may output the eye image to a blob analysis unit 13. The results of the blob analysis may be evaluated with IQM's for parameter estimates to stage the parameter ranges.


IQM1 may be indicated whether there the image has a valid eye at symbol 21. IQM1 is described in FIG. 2 and corresponding text hereon. If the capture of the eye in not deemed valid, the process might stop as symbol 31. If valid, then the eye image may go to symbol 22 for a blur measure according an IQM2, as described in FIGS. 3 and 4, and corresponding text herein. If the results of IQM2 at symbol 22 relative to a blur measure are not good, then the process may stop at symbol 32. If the results of IQM2 evaluation at symbol 22 are acceptable, then the pupil may be a segmented at block 14. After block 14, a gazed eye measure may be made at item 23 in view of an IQM3. Also, an eye may from the blob analysis unit 13 may to go an offset or shifted eye block 24 for an eye offset or shift measurement according to IQM4. IQM3 and IQM4 are described in FIG. 5 and corresponding text herein. The eye offset measurement from block 24 may be joined with the output of gazed eye measurement from block 23. These outputs may go to symbol 15 where a question whether the eye of the image is offset or gazed. If the eye is offset or gazed, then the iris may be segmented with no-circular calibration at block 16. If the eye is not offset or gazed, then the iris may be segmented with circular calibration at block 17.


The segment iris at the output of block 16 or 17 may go to a symbol that checks whether the eye or iris is obscured according to IQM6, as shown in FIG. 6 and corresponding text herein. If the result of symbol 26 is not acceptable, then the process may stop at symbol 36. If it is acceptable, then the eye or iris image may go to a block 18 where a map of the iris may be extracted. From block 18, the resultant map image may go to a symbol 25 where a visibility measure is made according to IQM5, as shown in FIGS. 6a and 6b and corresponding text herein. If the measure is not acceptable, the process may stop at symbol 35. If acceptable, then a multi-band code may be made of the iris at block 19. Also a single band-code may be made at block 27. Either or both codes from blocks 19 and 27 may go to a block 28 for a match to identify the iris and indicate possibly the identity of the person associated with the iris. Also, the one or both codes may be indexed and stored in a database for future use, such as identification.


IQM1 for eye validation, as shown in FIG. 2, may begin with an elliptic fitting having a controlled samples consensus algorithm (CSCA) at block 41. Following block 41, the fitness may be computed as a number of edges within a range of the estimated ellipse/total number of edges at block 42. The fitness may be checked at symbol 43 to note that it is less than THR1. If not, stop process and return quality 85.


Circular fitting on a Hough-based method may be implemented on the iris at block 44. The fitness may be computed as a number of edges within a range of the estimated circle/total number of edges at block 45. The fitness may be checked to see that it is less than THR2 at symbol 46. If not, then stop process and return quality 86. After symbol 46, an upper portion of the iris contour may be masked at block 47. Circular fitting may be done with the Hough-based method at block 48. At block 49, fitness may be computed as a number of edges within a range of the estimated circle/total number of non-masked regions or portions edges. One may go to return quality 87.


It may be noted that at least four combinations can be used to fit an elliptic model using the guided CSSA algorithm as a modification to random consensus algorithm and replacement of Hough transform. They include the sclera only, sclera plus the lower lid, the entire contour, and the lower portion of the contour.



FIG. 3
a is an outline of the IQM2 image blur assessment or measure. An eye image 50 may go to a block 51 to be decimated at, for instance, M×N=120×160. An operator may be applied to the decimated image at block 52. An example may be a Sobel operator 29 shown in FIG. 3b. An output after an application of the operator may go to a gradient equation at block 53, such as for example a Scharr filter 33 shown in FIG. 3c. The value of the output of block 53 should have a value greater than “θ” as indicated at symbol 54 to be acceptable.


A basic concept of the image blur assessment or measure IMQ2 may be noted in conjunction with a pixel distribution. Properties of a neighborhood pixel distribution may be considered using a gradient of the overall acquired image. The isotropic derivative operator on the image may show located edges at the borders of an iris consistently regardless of image quality (e.g., blur or focused images), which means that a quantified amount of edges is expected to be in the image gradient. For instance, θ=(2π(Rin+Rout))/(M×N). In the present example, θ=(2π(18+38))/(120×160)≈0.018. However, a value smaller than this estimate may be deemed as a blur image, and any value comparable or higher than this number may be deemed to be non-blur. This approach or method of locating other edges may appear characteristic of the “gradient filter” family of edge detection filters and includes an operator. Thus, for non-blur images, one may expect additional detected edges that exceed the amount computed for θ. An image may be declared a blur if the value of the cumulative sum of the gradient exceeds the computed threshold θ.


Another concept of the image blur assessment or measure IMQ2 may be noted in conjunction with FIG. 4. A zero crossing may be applied to find edges at all directions. A Laplacian approach may find edges regardless of orientation. One may look for a zero-crossing second derivative, that is, a Laplacian approach may be applied using a derivative for 1st-derivative extrema. It may be a Laplacian of the Gaussian (LOG) (linear and isotropic),

LoGσ=−(1/(πσ4)) (1−(x2+y2/2σ2))e−((x2+y2)/2σ2)).

Thus, one may search for the zero crossings of a Gaussian smoothed image with an operator 40. An example of an operator 40 may be a Marr-Hildreth one.


An image 60 of an eye may be provided to a block 61 for a crop at center, as indicated by a rectangle 55 of image 60 and with a formula (2Rout)×(2Rout). The cropped image encompassing the iris of the eye may go to blocks 62 and 63 for Gaussian smoothing and application of a formula, for example,










2


I

=







2


I




x


+






2


I




y




,





which together constitute the operator 40. The operator should preserve the texture of the image. Another formula may suffice for block 63. The output from block 63 may to a block 64 for a filtering or evaluation with a formula, for example,







1

4


R
OUT
2








x
,
y







I


(

x
,
y

)



.







Another formula may suffice for block 64. The output of block 64 may be checked at symbol 65 to see whether it exceeds “θ”, where θ=(π(Rin+Rout))/2Rout.


Eye gazing and offset may be evaluated in accordance with IQM3 and IQM4, respectively. Items of FIG. 5 illustrate such evaluation. A measurement may be made to assess the deformation of the iris perspective projection. The dimensions of the iris may be “b” (minor axis) and “a” (major axis), for instance a measurement of the outer bound in a direction along the y axis and in a direction along the x axis, respectively, as indicated by item 56. The measurement for deformation assessment may be indicated by a formula in box 57. The gazing deformation can be estimated using an approximation as being indicated by a formula. An applicable formula may be







4

a




0

π
2






1
-




a
2

-

b
2



a
2





sin
2



(
θ
)








θ




,





which may be approximated by formula,






2

π





1
2



(


a
2

+

b
2


)



.






Computing the surface of the inner bound may be another approach. For an aspect ratio of 0.36<(b/a)<2.94, the maximum error should be about 5 percent. For an aspect ratio of 0.12<(b/a)<10.77, the maximum error should be about 10 percent. A rough estimation of area may be indicated by “πab” in box 58. A calculation relative to offset can be computed by validating the center of the model C(x,y) such as the Rmax of the model satisfies the formulas in box 59. which are









c


(

x
,
y

)



,

{






R
max

<
x
<

(

cols
-

R
max


)








R
max

<
y
<

(

rows
-

R
max


)





,
and







c may be the center and Rmax=max expected value of the radius of the estimated model (E[radius]). If one measures the outer bound from the center of the iris along the x axis, and the distance in the x direction is less than the maximum radius of the outer bound Rmax, then there may be an offset.


The visibility measure according to IQM5 and obscuration measure according to IQM6 are shown in FIG. 6a. The outer boundary of the iris may be fitted into a model. A fitness measure is how good the model may fit the curve of the boundary. It the conditional statements 66 and 67 are met, then the statement 68 for an IQM5 visibility measurement may follow. Statement 66 is







if










(


m
U

=



1

A
U







Θ
U




mask


(


:

,
θ

)




>

λ
U



)

,


mask


(


:

,

Θ
U


)


=
1






and statement 67 is







if






(


m
L

=



1

A
L







Θ
L




mask


(


:

,
θ

)




>

λ
L



)


,


mask


(


:

,

Θ
L


)


=
1






Statement 68 is







m

IQM





5


=


1
A





Θ



mask


(


:

,
θ

)









A statement 69 for an IQM6 measurement is







m

IQM





6


=


1
Θ





Θ



u


(

λ
-






m
θ



(

x
,
y

)


-


e
θ



(

x
,
y

)





2


)









FIG. 6
b shows maps 34, and portions that should be masked to eliminate noise.



FIGS. 7
a and 7b provide an approach for quadrant iris analysis, that is, an analysis quadrant by quadrant. Step 1 may include finding limits on the top left quadrant 71. One may start from the sclera at an x axis, clockwise, and proceed to a break point at an obscuration or discontinuity, if any. If there is no obscuration, discontinuity or the like, then a break point may be defined between the first and second quadrants (i.e., upper left and right quadrants). Such defined break may be about 90 degrees or so clockwise from the 0 degree point at the x-axis in the first quadrant or about 90 degrees counterclockwise from the 180 degree point from the x-axis in the second quadrant.


The statements in box 75 may be used for quadrant analysis as indicated herein.








θ


[



θ


TL

,


θ


TR


]











if






(





θ
l

/






e
θ




θ





>
λ


)








θ
TL


=

θ
l












else






θ
TL


=



θ


TR

-
1.








Step 2 may include finding limits of the top right quadrant 72. One may start from the sclera, counterclockwise. If there is no obscuration, discontinuity or the like, then a break point may be defined between the first and second quadrants as noted in step 1. If there is no obscuration, discontinuity or the like, then a break point may be defined between the first and second quadrants. The statements in box 76 may be used as indicated herein.








θ


[


θ
TL

,


θ


TR


]











if






(





θ
r

/






e
θ




θ





>
λ


)








θ
TR


=

θ
r













else






θ
TR


=


θ


TR





.




Step 3 may include an interpolation/mask test. The statements as stated in box 77 may be used as indicated herein.

if (|θTR−θTLλ′|)custom charactermask(:,θTLTR)=1
elsecustom characterlinear interpolation


Steps 4 and 5 use the same statements as steps 1 and 2 except quadrants TL 71 and TR 72 may be substituted with quadrants BL 73 and BR 74, respectively. The same substitution may apply for step 6 in lieu of step 3. Full segmentation (i.e., no masking) may be used. Full segmentation is equivalent to a single point interpolation.


One may start at 0 degrees with respect to the x axis (x-axis may change based upon head tilting and is always assumed to be the normal of the head orientation, that passes by the two eye centers; y-axis is the normal direction of the x-axis that defines the head orientation) in the left quadrant and move out to a break point. When the break point is encountered, then that portion of the quadrant may become TL. Generally the break point will be a discontinuity such as an eyelash. If there is no break point, the edges of POSE are preserved (as good edges) and process is completed toward specified limits. The low left and right quadrants may be handled similarly.


In the quadrant pairs TL and TR and BL and BR, the break points may not exist in case of an open eye with no eye lid obscurations. The POSE edges are applicable as captured by original algorithm POSE. An obscuration between the break points may determine an angle between the break points. An angle θo may be determined as an interpolation, i.e., a line between the break points. If there is a large angle, then both quadrants, i.e., TL and TR, may be blocked with masking. For example, an angle of 100 degrees may leave little iris left in the two quadrants.



FIG. 8 is a graph 78 of histogram data versus intensity values for typical pixel distributions. One may discriminate between iris and non-iris pixels by clustering pixel distributions. This process relates to map analysis involving a stage for extracting outliers in the iris map. The may be clusters 37 and 38 of pixels outliers. Cluster 37 may be set out by valleys 39 and 79 in the histogram 78. The iris pixels should be part of just one cluster as the color of the iris would tend to result in pixels having a similar intensity since there is generally one overall color in the iris. Cluster 37 appears to be the one with the iris pixels. Cluster 38 would then be noise such a blocked lower portion of the iris or a bright reflective spot on the iris which may be regarded as an outlier. Such portion may be masked out in an iris map. Additional filtering may be considered at the feature extraction stage to clean up outliers from the iris map. There may be no need to add another segmentation process in the lower lid segmentation.


There may be leaked pixels from a cluster to another due to poor segmentation or other artifacts, e.g., reflections. Thus searching for the valley points among cluster may result in misplacement of the actual limits of the clusters. Thus one may impose limitations on the extent of valley searches by guaranteeing at least 90 percent of the iris pixels to be within the iris cluster. FIG. 9 shows an extension of intensity ranges associated with the imposed limits and a statement (i.e., formulas) of how to obtain these limits. There may be a certain percentage (e.g., 90 percent) of a distribution that covers a prominent cluster which likely represents the iris. An extraneous cluster outside the certain percentage of the distribution may represent noise subject to removal (10 percent expected percentage of noisy pixels).

{tilde over (x)}max=max(xσ, xλR)
{tilde over (x)}min=min(−xσ, xλL)


Such that










-

x
σ



x
σ





1

σ



2

π









-

1
2





(


x
-
μ

σ

)

2





>

90

%






Where λR and λL are the detected valleys in the right and left side of the iris pixel cluster. The cluster 37 of pixels represents the iris. Extraneous clusters 38 and 81 may be noted on both sides of cluster 37, separated by valleys 39 and 79, respectively. The iris map may be adaptively threshholded on the basis of intensity of the pixels. Assuming normal distribution, one would seek to keep 90 percent of the area of pixels including the main cluster 37. One may impose limits left and right at lines 82 and 83, respectively, or both to obtain at most 90 percent coverage. The 90 percent approach, although it could be another percentage especially if there is no valley or only one valley to separate or distinguish cluster 37, may guarantee enough area of the iris with cluster 37 for matching, analysis, identification, and/or the like. The remaining area is generally noise which may be removed.



FIG. 10 illustrates a multi-band (i.e., frequency) analysis with a showing of one, two and three banks 84 of code bits related to an iris. Each bank may have a filter and weighted appropriately in the matching process.


In the present specification, some of the matter may be of a hypothetical or prophetic nature although stated in another manner or tense.


Although the invention has been described with respect to at least one illustrative example, many variations and modifications will become apparent to those skilled in the art upon reading the present specification. It is therefore the intention that the appended claims be interpreted as broadly as possible in view of the prior art to include all such variations and modifications.

Claims
  • 1. A method for iris recognition comprising: locating an eye with a camera;obtaining an image of the eye with the camera;assessing the image of the eye with a set of image quality metrics with a processor; andsegmenting the iris in the image of the eye with the processor;wherein the set of image quality metrics comprises: an offset measurement of the eye in the image of the eye; anda gaze measurement of the eye in the image of the eye;wherein a calibration of the segmenting of the iris is determined by the offset and gaze measurements; andwherein: if the offset and gaze measurements indicate offset or gaze of the eye in the image of the eye, then the segmenting of the iris is based on no circular calibration; andif the offset and gaze measurements. indicate no offset or gaze of the eye, then the segmenting of the iris is based on circular calibration.
  • 2. The method of claim 1, further comprising determining a quality score of the image of the eye with the set of image quality metrics with the processor.
  • 3. The method of claim 2, further comprising: determining a matching score of the image of the eye based on matches of the image of the eye with other images of the eye with the processor; andestablishing an evaluation score based on the quality score and the matching score with the processor.
  • 4. The method of claim 1, wherein the set of image quality metrics further comprises: a validity measurement of the image of the eye; anda blur measurement of the image of the eye.
  • 5. A method for iris recognition comprising: locating an eye with a camera;obtaining an image of the eye with the camera; andassessing the image of the eye with a set of image quality metrics with a processor; andsegmenting the iris in the image of the eye with the processor;wherein the set of image quality metrics comprises: an offset measurement of the eye in the image of the eye; anda gaze measurement of the eye in the image of the eye;wherein a calibration of the segmenting of the iris is determined by the offset and gaze measurements;wherein the set of image quality metrics further comprises: an obscuration measurement of the eye in the image of the eye; anda visibility measurement of the iris of the eye; andwherein: if the obscuration measurement of the eye reveals the eye not to be obscured, then a map of an iris of the eye is extracted with the processor; anda visibility measurement of the iris in the map of the iris is made with the processor.
  • 6. The method of claim 5, further comprising: coding the iris in a single band code and/or multi-band code with associated weights based on the image quality metrics with the processor; andmatching the single band code and/or multi-band code with other codes of the iris with the processor.
  • 7. The method of claim 6, wherein the set of image quality metrics further comprises: a validity measurement of the image of the eye; anda blur measurement of the image of the eye; andwherein the associated weights based on the image quality metrics used in coding the iris are based at least in part on the blur measurement.
  • 8. A method for iris recognition comprising: locating an eye with a camera;obtaining an image of the eye with the camera; andassessing the image of the eye with a set of image quality metrics with a processor; andsegmenting the iris in the image of the eye with the processor;wherein the set of image quality metrics comprises: an offset measurement of the eye in the image of the eye; anda gaze measurement of the eye in the image of the eye;wherein a calibration of the segmenting of the iris is determined by the offset and gaze measurements; andwherein segmenting the iris includes a quadrant iris analysis performed with the processor, the quadrant iris analysis comprising: finding a first limit in a first quadrant toward a second quadrant, starting from a sclera in a first direction;finding a second limit in newly defined second quadrant based on the first limit, starting from the sclera at the horizontal axis in a second direction opposite the first direction;applying an interpolation/mask test to the first and second quadrants;finding limits in a third quadrant in a direction toward a fourth quadrant;finding limits in a newly defined fourth quadrant in an opposite direction; andapplying an interpolation/mask test to the third and fourth quadrants.
  • 9. A system for iris recognition using quality metrics, comprising: an eye image source;a quality metric mechanism connected to the eye image source;an iris map extractor connected to the quality metric mechanism and configured to extract a map of an iris; anda processor configured to eliminate intensity outliers in the map;wherein clustering pixel intensities of the map is based on their distributed histogram by selectively choosing limits of the iris as represented in the map using associated valleys on the left and right of an iris pixel cluster.
  • 10. A system for iris recognition using quality metrics, comprising: an eye image source;a quality metric mechanism connected to the eye image source; and an iris map extractor connected to the quality metric mechanism and configured to extract a map of an iris;wherein:a limited range is imposed to preserve a certain percentage of pixel elements of a prominent pixel cluster which likely represents the iris in the map; andan element beyond the limited range or the estimated thresholds of the pixel cluster represents noise subject to removal.
US Referenced Citations (402)
Number Name Date Kind
4641349 Flom et al. Feb 1987 A
4836670 Hutchinson Jun 1989 A
5231674 Cleveland et al. Jul 1993 A
5291560 Daugman Mar 1994 A
5293427 Ueno et al. Mar 1994 A
5359382 Uenaka Oct 1994 A
5404013 Tajima Apr 1995 A
5551027 Choy et al. Aug 1996 A
5572596 Wildes et al. Nov 1996 A
5608472 Szirth et al. Mar 1997 A
5664239 Nakata Sep 1997 A
5687031 Ishihara Nov 1997 A
5717512 Chmielewski, Jr. et al. Feb 1998 A
5751836 Wildes et al. May 1998 A
5859686 Aboutalib et al. Jan 1999 A
5860032 Iwane Jan 1999 A
5896174 Nakata Apr 1999 A
5901238 Matsushita May 1999 A
5909269 Isogai et al. Jun 1999 A
5953440 Zhang et al. Sep 1999 A
5956122 Doster Sep 1999 A
5978494 Zhang Nov 1999 A
6005704 Chmielewski, Jr. et al. Dec 1999 A
6007202 Apple et al. Dec 1999 A
6012376 Hanke et al. Jan 2000 A
6021210 Camus et al. Feb 2000 A
6028949 McKendall Feb 2000 A
6055322 Salganicoff et al. Apr 2000 A
6064752 Rozmus et al. May 2000 A
6069967 Rozmus et al. May 2000 A
6081607 Mori et al. Jun 2000 A
6088470 Camus et al. Jul 2000 A
6091899 Konishi et al. Jul 2000 A
6101477 Hohle et al. Aug 2000 A
6104431 Inoue et al. Aug 2000 A
6108636 Yap et al. Aug 2000 A
6119096 Mann et al. Sep 2000 A
6120461 Smyth Sep 2000 A
6134339 Luo Oct 2000 A
6144754 Okano et al. Nov 2000 A
6246751 Bergl et al. Jun 2001 B1
6247813 Kim et al. Jun 2001 B1
6252977 Salganicoff et al. Jun 2001 B1
6259478 Hori Jul 2001 B1
6282475 Washington Aug 2001 B1
6285505 Melville et al. Sep 2001 B1
6285780 Yamakita et al. Sep 2001 B1
6289113 McHugh et al. Sep 2001 B1
6299306 Braithwaite et al. Oct 2001 B1
6308015 Matsumoto Oct 2001 B1
6309069 Seal et al. Oct 2001 B1
6320610 Van Sant et al. Nov 2001 B1
6320612 Young Nov 2001 B1
6320973 Suzaki et al. Nov 2001 B2
6323761 Son Nov 2001 B1
6325765 Hay et al. Dec 2001 B1
6330674 Angelo et al. Dec 2001 B1
6332193 Glass et al. Dec 2001 B1
6344683 Kim Feb 2002 B1
6370260 Pavlidis et al. Apr 2002 B1
6377699 Musgrave et al. Apr 2002 B1
6393136 Amir et al. May 2002 B1
6400835 Lemelson et al. Jun 2002 B1
6424727 Musgrave et al. Jul 2002 B1
6424845 Emmoft et al. Jul 2002 B1
6433818 Steinberg et al. Aug 2002 B1
6438752 McClard Aug 2002 B1
6441482 Foster Aug 2002 B1
6446045 Stone et al. Sep 2002 B1
6483930 Musgrave et al. Nov 2002 B1
6484936 Nicoll et al. Nov 2002 B1
6490443 Freeny, Jr. Dec 2002 B1
6493669 Curry et al. Dec 2002 B1
6494363 Roger et al. Dec 2002 B1
6503163 Van Sant et al. Jan 2003 B1
6505193 Musgrave et al. Jan 2003 B1
6506078 Mori et al. Jan 2003 B1
6508397 Do Jan 2003 B1
6516078 Yang et al. Feb 2003 B1
6516087 Camus Feb 2003 B1
6516416 Gregg et al. Feb 2003 B2
6522772 Morrison et al. Feb 2003 B1
6523165 Liu et al. Feb 2003 B2
6526160 Ito Feb 2003 B1
6532298 Cambier et al. Mar 2003 B1
6540392 Braithwaite Apr 2003 B1
6542624 Oda Apr 2003 B1
6546121 Oda Apr 2003 B1
6553494 Glass Apr 2003 B1
6580356 Alt et al. Jun 2003 B1
6591001 Oda et al. Jul 2003 B1
6591064 Higashiyama et al. Jul 2003 B2
6594377 Kim et al. Jul 2003 B1
6594399 Camus et al. Jul 2003 B1
6598971 Cleveland Jul 2003 B2
6600878 Pregara Jul 2003 B2
6614919 Suzaki et al. Sep 2003 B1
6652099 Chae et al. Nov 2003 B2
6674367 Sweatte Jan 2004 B2
6690997 Rivalto Feb 2004 B2
6708176 Strunk et al. Mar 2004 B2
6711562 Ross et al. Mar 2004 B1
6714665 Hanna et al. Mar 2004 B1
6718049 Pavlidis et al. Apr 2004 B2
6718665 Hess et al. Apr 2004 B2
6732278 Baird, III et al. May 2004 B2
6734783 Anbai May 2004 B1
6745520 Yesh et al. Jun 2004 B2
6750435 Ford Jun 2004 B2
6751733 Nakamura et al. Jun 2004 B1
6753919 Daugman Jun 2004 B1
6754640 Bozeman Jun 2004 B2
6760467 Min et al. Jul 2004 B1
6765470 Shinzaki Jul 2004 B2
6766041 Golden et al. Jul 2004 B2
6775774 Harper Aug 2004 B1
6785406 Kamada Aug 2004 B1
6793134 Clark Sep 2004 B2
6819219 Bolle et al. Nov 2004 B1
6829370 Pavlidis et al. Dec 2004 B1
6832044 Doi et al. Dec 2004 B2
6836554 Bolle et al. Dec 2004 B1
6837436 Swartz et al. Jan 2005 B2
6845879 Park Jan 2005 B2
6853444 Haddad Feb 2005 B2
6867683 Calvesio et al. Mar 2005 B2
6873960 Wood et al. Mar 2005 B1
6896187 Stockhammer May 2005 B2
6905411 Nguyen et al. Jun 2005 B2
6920237 Chen et al. Jul 2005 B2
6930707 Bates et al. Aug 2005 B2
6934849 Kramer et al. Aug 2005 B2
6950139 Fujinawa Sep 2005 B2
6954738 Wang et al. Oct 2005 B2
6957341 Rice et al. Oct 2005 B2
6972797 Izumi Dec 2005 B2
6992562 Fuks et al. Jan 2006 B2
7030351 Wasserman et al. Apr 2006 B2
7053948 Konishi May 2006 B2
7071971 Elberbaum Jul 2006 B2
7084904 Liu et al. Aug 2006 B2
7136581 Fujii Nov 2006 B2
7183895 Bazakos et al. Feb 2007 B2
7184577 Chen et al. Feb 2007 B2
7197173 Jones et al. Mar 2007 B2
7204425 Mosher, Jr. et al. Apr 2007 B2
7277561 Shin Oct 2007 B2
7277891 Howard et al. Oct 2007 B2
7298873 Miller, Jr. et al. Nov 2007 B2
7298874 Cho Nov 2007 B2
7315233 Yuhara Jan 2008 B2
7362210 Bazakos et al. Apr 2008 B2
7362370 Sakamoto et al. Apr 2008 B2
7362884 Willis et al. Apr 2008 B2
7365771 Kahn et al. Apr 2008 B2
7380938 Chmielewski, Jr. et al. Jun 2008 B2
7406184 Wolff et al. Jul 2008 B2
7414648 Imada Aug 2008 B2
7417682 Kuwakino et al. Aug 2008 B2
7418115 Northcott et al. Aug 2008 B2
7421097 Hamza et al. Sep 2008 B2
7443441 Hiraoka Oct 2008 B2
7460693 Loy et al. Dec 2008 B2
7471451 Dent et al. Dec 2008 B2
7486806 Azuma et al. Feb 2009 B2
7518651 Butterworth Apr 2009 B2
7537568 Moehring May 2009 B2
7538326 Johnson et al. May 2009 B2
7542945 Thompson et al. Jun 2009 B2
7580620 Raskar et al. Aug 2009 B2
7593550 Hamza Sep 2009 B2
7639846 Yoda Dec 2009 B2
7722461 Gatto et al. May 2010 B2
7751598 Matey et al. Jul 2010 B2
7756301 Hamza Jul 2010 B2
7756407 Raskar Jul 2010 B2
7761453 Hamza Jul 2010 B2
7777802 Shinohara et al. Aug 2010 B2
7804982 Howard et al. Sep 2010 B2
8045764 Hamza Oct 2011 B2
20010026632 Tamai Oct 2001 A1
20010027116 Baird Oct 2001 A1
20010047479 Bromba et al. Nov 2001 A1
20010051924 Uberti Dec 2001 A1
20010054154 Tam Dec 2001 A1
20020010857 Karthik Jan 2002 A1
20020033896 Hatano Mar 2002 A1
20020039433 Shin Apr 2002 A1
20020040434 Elliston et al. Apr 2002 A1
20020062280 Zachariassen et al. May 2002 A1
20020077841 Thompson Jun 2002 A1
20020089157 Breed et al. Jul 2002 A1
20020106113 Park Aug 2002 A1
20020112177 Voltmer et al. Aug 2002 A1
20020114495 Chen et al. Aug 2002 A1
20020130961 Lee et al. Sep 2002 A1
20020131622 Lee et al. Sep 2002 A1
20020139842 Swaine Oct 2002 A1
20020140715 Smet Oct 2002 A1
20020142844 Kerr Oct 2002 A1
20020144128 Rahman et al. Oct 2002 A1
20020150281 Cho Oct 2002 A1
20020154794 Cho Oct 2002 A1
20020158750 Almalik Oct 2002 A1
20020164054 McCartney et al. Nov 2002 A1
20020175182 Matthews Nov 2002 A1
20020186131 Fettis Dec 2002 A1
20020191075 Doi et al. Dec 2002 A1
20020191076 Wada et al. Dec 2002 A1
20020194128 Maritzen et al. Dec 2002 A1
20020194131 Dick Dec 2002 A1
20020198731 Barnes et al. Dec 2002 A1
20030002714 Wakiyama Jan 2003 A1
20030012413 Kusakari et al. Jan 2003 A1
20030014372 Wheeler et al. Jan 2003 A1
20030020828 Ooi et al. Jan 2003 A1
20030038173 Blackson et al. Feb 2003 A1
20030046228 Berney Mar 2003 A1
20030053663 Chen et al. Mar 2003 A1
20030055689 Block et al. Mar 2003 A1
20030055787 Fujii Mar 2003 A1
20030058492 Wakiyama Mar 2003 A1
20030061172 Robinson Mar 2003 A1
20030061233 Manasse et al. Mar 2003 A1
20030065626 Allen Apr 2003 A1
20030071743 Seah et al. Apr 2003 A1
20030072475 Tamori Apr 2003 A1
20030073499 Reece Apr 2003 A1
20030074317 Hofi Apr 2003 A1
20030074326 Byers Apr 2003 A1
20030076161 Tisse Apr 2003 A1
20030076300 Lauper et al. Apr 2003 A1
20030076984 Tisse et al. Apr 2003 A1
20030080194 O'Hara et al. May 2003 A1
20030091215 Lauper et al. May 2003 A1
20030092489 Veradej May 2003 A1
20030095689 Volkommer et al. May 2003 A1
20030098776 Friedli May 2003 A1
20030099379 Monk et al. May 2003 A1
20030099381 Ohba May 2003 A1
20030103652 Lee et al. Jun 2003 A1
20030107097 McArthur et al. Jun 2003 A1
20030107645 Yoon Jun 2003 A1
20030108224 Ike Jun 2003 A1
20030108225 Li Jun 2003 A1
20030115148 Takhar Jun 2003 A1
20030115459 Monk Jun 2003 A1
20030116630 Carey et al. Jun 2003 A1
20030118212 Min et al. Jun 2003 A1
20030118217 Kondo et al. Jun 2003 A1
20030123711 Kim et al. Jul 2003 A1
20030125054 Garcia Jul 2003 A1
20030125057 Pesola Jul 2003 A1
20030126560 Kurapati et al. Jul 2003 A1
20030131245 Linderman Jul 2003 A1
20030131265 Bhakta Jul 2003 A1
20030133597 Moore et al. Jul 2003 A1
20030140235 Immega et al. Jul 2003 A1
20030140928 Bui et al. Jul 2003 A1
20030141411 Pandya et al. Jul 2003 A1
20030149881 Patel et al. Aug 2003 A1
20030152251 Ike Aug 2003 A1
20030152252 Kondo et al. Aug 2003 A1
20030156741 Lee et al. Aug 2003 A1
20030158762 Wu Aug 2003 A1
20030158821 Maia Aug 2003 A1
20030159051 Hollnagel Aug 2003 A1
20030163739 Armington et al. Aug 2003 A1
20030169334 Braithwaite et al. Sep 2003 A1
20030169901 Pavlidis et al. Sep 2003 A1
20030169907 Edwards et al. Sep 2003 A1
20030173408 Mosher, Jr. et al. Sep 2003 A1
20030174049 Beigel et al. Sep 2003 A1
20030177051 Driscoll et al. Sep 2003 A1
20030182151 Taslitz Sep 2003 A1
20030182182 Kocher Sep 2003 A1
20030189480 Hamid Oct 2003 A1
20030189481 Hamid Oct 2003 A1
20030191949 Odagawa Oct 2003 A1
20030194112 Lee Oct 2003 A1
20030195935 Leeper Oct 2003 A1
20030198368 Kee Oct 2003 A1
20030200180 Phelan, III et al. Oct 2003 A1
20030210139 Brooks et al. Nov 2003 A1
20030210802 Schuessier Nov 2003 A1
20030218719 Abourizk et al. Nov 2003 A1
20030225711 Paping Dec 2003 A1
20030228898 Rowe Dec 2003 A1
20030233556 Angelo et al. Dec 2003 A1
20030235326 Morikawa et al. Dec 2003 A1
20030235411 Morikawa et al. Dec 2003 A1
20030236120 Reece et al. Dec 2003 A1
20040001614 Russon et al. Jan 2004 A1
20040002894 Kocher Jan 2004 A1
20040005078 Tillotson Jan 2004 A1
20040006553 de Vries et al. Jan 2004 A1
20040010462 Moon et al. Jan 2004 A1
20040012760 Mihashi et al. Jan 2004 A1
20040019570 Bolle et al. Jan 2004 A1
20040023664 Mirouze et al. Feb 2004 A1
20040023709 Beaulieu et al. Feb 2004 A1
20040025030 Corbett-Clark et al. Feb 2004 A1
20040025031 Ooi et al. Feb 2004 A1
20040025053 Hayward Feb 2004 A1
20040029564 Hodge Feb 2004 A1
20040030930 Nomura Feb 2004 A1
20040035123 Kim et al. Feb 2004 A1
20040037450 Bradski Feb 2004 A1
20040039914 Barr et al. Feb 2004 A1
20040042641 Jakubowski Mar 2004 A1
20040044627 Russell et al. Mar 2004 A1
20040046640 Jourdain et al. Mar 2004 A1
20040049687 Orsini et al. Mar 2004 A1
20040050924 Mletzko et al. Mar 2004 A1
20040050930 Rowe Mar 2004 A1
20040052405 Walfridsson Mar 2004 A1
20040052418 DeLean Mar 2004 A1
20040059590 Mercredi et al. Mar 2004 A1
20040059953 Purnell Mar 2004 A1
20040104266 Bolle et al. Jun 2004 A1
20040117636 Cheng Jun 2004 A1
20040133804 Smith et al. Jul 2004 A1
20040146187 Jeng Jul 2004 A1
20040148526 Sands et al. Jul 2004 A1
20040160518 Park Aug 2004 A1
20040162870 Matsuzaki et al. Aug 2004 A1
20040162984 Freeman et al. Aug 2004 A1
20040169817 Grotehusmann et al. Sep 2004 A1
20040172541 Ando et al. Sep 2004 A1
20040174070 Voda et al. Sep 2004 A1
20040190759 Caldwell Sep 2004 A1
20040193893 Braithwaite et al. Sep 2004 A1
20040219902 Lee et al. Nov 2004 A1
20040233038 Beenau et al. Nov 2004 A1
20040240711 Hamza et al. Dec 2004 A1
20040252866 Tisse et al. Dec 2004 A1
20040255168 Murashita et al. Dec 2004 A1
20050008200 Azuma et al. Jan 2005 A1
20050008201 Lee et al. Jan 2005 A1
20050012817 Hampapur et al. Jan 2005 A1
20050029353 Isemura et al. Feb 2005 A1
20050052566 Kato Mar 2005 A1
20050055582 Bazakos et al. Mar 2005 A1
20050063567 Saitoh et al. Mar 2005 A1
20050084137 Kim et al. Apr 2005 A1
20050084179 Hanna et al. Apr 2005 A1
20050099288 Spitz et al. May 2005 A1
20050102502 Sagen May 2005 A1
20050110610 Bazakos et al. May 2005 A1
20050125258 Yellin et al. Jun 2005 A1
20050127161 Smith et al. Jun 2005 A1
20050129286 Hekimian Jun 2005 A1
20050134796 Zelvin et al. Jun 2005 A1
20050138385 Friedli et al. Jun 2005 A1
20050138387 Lam et al. Jun 2005 A1
20050146640 Shibata Jul 2005 A1
20050151620 Neumann Jul 2005 A1
20050152583 Kondo et al. Jul 2005 A1
20050193212 Yuhara Sep 2005 A1
20050199708 Friedman Sep 2005 A1
20050206501 Farhat Sep 2005 A1
20050206502 Bernitz Sep 2005 A1
20050207614 Schonberg et al. Sep 2005 A1
20050210267 Sugano et al. Sep 2005 A1
20050210270 Rohatgi et al. Sep 2005 A1
20050210271 Chou et al. Sep 2005 A1
20050238214 Matsuda et al. Oct 2005 A1
20050240778 Saito Oct 2005 A1
20050248725 Ikoma et al. Nov 2005 A1
20050249385 Kondo et al. Nov 2005 A1
20050255840 Markham Nov 2005 A1
20060093190 Cheng et al. May 2006 A1
20060147094 Yoo Jul 2006 A1
20060165266 Hamza Jul 2006 A1
20060274919 LoIacono et al. Dec 2006 A1
20070036397 Hamza Feb 2007 A1
20070140531 Hamza Jun 2007 A1
20070160266 Jones et al. Jul 2007 A1
20070189582 Hamza et al. Aug 2007 A1
20070206840 Jacobson Sep 2007 A1
20070211924 Hamza Sep 2007 A1
20070274570 Hamza Nov 2007 A1
20070274571 Hamza Nov 2007 A1
20070286590 Terashima Dec 2007 A1
20080005578 Shafir Jan 2008 A1
20080044070 Nie Feb 2008 A1
20080075334 Determan et al. Mar 2008 A1
20080075441 Jelinek et al. Mar 2008 A1
20080075445 Whillock et al. Mar 2008 A1
20080104415 Palti-Wasserman et al. May 2008 A1
20080148030 Goffin Jun 2008 A1
20080211347 Wright et al. Sep 2008 A1
20080252412 Larsson et al. Oct 2008 A1
20090046899 Northcott et al. Feb 2009 A1
20090092283 Whillock et al. Apr 2009 A1
20090316993 Brasnett et al. Dec 2009 A1
20100033677 Jelinek Feb 2010 A1
20100034529 Jelinek Feb 2010 A1
20100110374 Raguin et al. May 2010 A1
20100182440 McCloskey Jul 2010 A1
20100239119 Bazakos et al. Sep 2010 A1
20110150334 Du et al. Jun 2011 A1
Foreign Referenced Citations (188)
Number Date Country
0484076 May 1992 EP
0593386 Apr 1994 EP
0878780 Nov 1998 EP
0899680 Mar 1999 EP
0910986 Apr 1999 EP
0962894 Dec 1999 EP
1018297 Jul 2000 EP
1024463 Aug 2000 EP
1028398 Aug 2000 EP
1041506 Oct 2000 EP
1041523 Oct 2000 EP
1126403 Aug 2001 EP
1139270 Oct 2001 EP
1237117 Sep 2002 EP
1477925 Nov 2004 EP
1635307 Mar 2006 EP
2369205 May 2002 GB
2371396 Jul 2002 GB
2375913 Nov 2002 GB
2402840 Dec 2004 GB
2411980 Sep 2005 GB
9161135 Jun 1997 JP
9198545 Jul 1997 JP
9201348 Aug 1997 JP
9147233 Sep 1997 JP
9234264 Sep 1997 JP
9305765 Nov 1997 JP
9319927 Dec 1997 JP
10021392 Jan 1998 JP
10040386 Feb 1998 JP
10049728 Feb 1998 JP
10137219 May 1998 JP
10137221 May 1998 JP
10137222 May 1998 JP
10137223 May 1998 JP
10248827 Sep 1998 JP
10269183 Oct 1998 JP
11047117 Feb 1999 JP
11089820 Apr 1999 JP
11200684 Jul 1999 JP
11203478 Jul 1999 JP
11213047 Aug 1999 JP
11339037 Dec 1999 JP
2000005149 Jan 2000 JP
2000005150 Jan 2000 JP
2000011163 Jan 2000 JP
2000023946 Jan 2000 JP
2000083930 Mar 2000 JP
2000102510 Apr 2000 JP
2000102524 Apr 2000 JP
2000105830 Apr 2000 JP
2000107156 Apr 2000 JP
2000139878 May 2000 JP
2000155863 Jun 2000 JP
2000182050 Jun 2000 JP
2000185031 Jul 2000 JP
2000194972 Jul 2000 JP
2000237167 Sep 2000 JP
2000242788 Sep 2000 JP
2000259817 Sep 2000 JP
2000356059 Dec 2000 JP
2000357232 Dec 2000 JP
2001005948 Jan 2001 JP
2001067399 Mar 2001 JP
2001101429 Apr 2001 JP
2001167275 Jun 2001 JP
2001222661 Aug 2001 JP
2001292981 Oct 2001 JP
2001297177 Oct 2001 JP
2001358987 Dec 2001 JP
2002119477 Apr 2002 JP
2002133415 May 2002 JP
2002153444 May 2002 JP
2002153445 May 2002 JP
2002260071 Sep 2002 JP
2002271689 Sep 2002 JP
2002286650 Oct 2002 JP
2002312772 Oct 2002 JP
2002329204 Nov 2002 JP
2003006628 Jan 2003 JP
2003036434 Feb 2003 JP
2003108720 Apr 2003 JP
2003108983 Apr 2003 JP
2003132355 May 2003 JP
2003150942 May 2003 JP
2003153880 May 2003 JP
2003242125 Aug 2003 JP
2003271565 Sep 2003 JP
2003271940 Sep 2003 JP
2003308522 Oct 2003 JP
2003308523 Oct 2003 JP
2003317102 Nov 2003 JP
2003331265 Nov 2003 JP
2004005167 Jan 2004 JP
2004021406 Jan 2004 JP
2004030334 Jan 2004 JP
2004038305 Feb 2004 JP
2004094575 Mar 2004 JP
2004152046 May 2004 JP
2004163356 Jun 2004 JP
2004164483 Jun 2004 JP
2004171350 Jun 2004 JP
2004171602 Jun 2004 JP
2004206444 Jul 2004 JP
2004220376 Aug 2004 JP
2004261515 Sep 2004 JP
2004280221 Oct 2004 JP
2004280547 Oct 2004 JP
2004287621 Oct 2004 JP
2004315127 Nov 2004 JP
2004318248 Nov 2004 JP
2005004524 Jan 2005 JP
2005011207 Jan 2005 JP
2005025577 Jan 2005 JP
2005038257 Feb 2005 JP
2005062990 Mar 2005 JP
2005115961 Apr 2005 JP
2005148883 Jun 2005 JP
2005242677 Sep 2005 JP
WO 9717674 May 1997 WO
WO 9721188 Jun 1997 WO
WO 9802083 Jan 1998 WO
WO 9808439 Mar 1998 WO
WO 9932317 Jul 1999 WO
WO 9952422 Oct 1999 WO
WO 9965175 Dec 1999 WO
WO 0028484 May 2000 WO
WO 0029986 May 2000 WO
WO 0031677 Jun 2000 WO
WO 0036605 Jun 2000 WO
WO 0062239 Oct 2000 WO
WO 0101329 Jan 2001 WO
WO 0103100 Jan 2001 WO
WO 0128476 Apr 2001 WO
WO 0135348 May 2001 WO
WO 0135349 May 2001 WO
WO 0140982 Jun 2001 WO
WO 0163994 Aug 2001 WO
WO 0169490 Sep 2001 WO
WO 0186599 Nov 2001 WO
WO 0201451 Jan 2002 WO
WO 0219030 Mar 2002 WO
WO 0235452 May 2002 WO
WO 0235480 May 2002 WO
WO 02091735 Nov 2002 WO
WO 02095657 Nov 2002 WO
WO 03002387 Jan 2003 WO
WO 03003910 Jan 2003 WO
WO 03054777 Jul 2003 WO
WO 03077077 Sep 2003 WO
WO 2004029863 Apr 2004 WO
WO 2004042646 May 2004 WO
WO 2004055737 Jul 2004 WO
WO 2004089214 Oct 2004 WO
WO 2004097743 Nov 2004 WO
WO 2005008567 Jan 2005 WO
WO 2005013181 Feb 2005 WO
WO 2005024698 Mar 2005 WO
WO 2005024708 Mar 2005 WO
WO 2005024709 Mar 2005 WO
WO 2005029388 Mar 2005 WO
WO 2005062235 Jul 2005 WO
WO 2005069252 Jul 2005 WO
WO 2005093510 Oct 2005 WO
WO 2005093681 Oct 2005 WO
WO 2005096962 Oct 2005 WO
WO 2005098531 Oct 2005 WO
WO 2005104704 Nov 2005 WO
WO 2005109344 Nov 2005 WO
WO 2006012645 Feb 2006 WO
WO 2006023046 Mar 2006 WO
WO 2006051462 May 2006 WO
WO 2006063076 Jun 2006 WO
WO 2006081209 Aug 2006 WO
WO 2006081505 Aug 2006 WO
2007101269 Sep 2007 WO
WO 2007101275 Sep 2007 WO
WO 2007101276 Sep 2007 WO
WO 2007103698 Sep 2007 WO
WO 2007103701 Sep 2007 WO
WO 2007103833 Sep 2007 WO
WO 2007103834 Sep 2007 WO
WO 2008016724 Feb 2008 WO
WO 2008019168 Feb 2008 WO
WO 2008019169 Feb 2008 WO
WO 2008021584 Feb 2008 WO
WO 2008031089 Mar 2008 WO
WO 2008040026 Apr 2008 WO
Related Publications (1)
Number Date Country
20100142765 A1 Jun 2010 US